ArticleDiscover oncology2025
Pan-cancer atlas analysis of FANCB and its potential mechanism in cholangiocarcinoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Double jeopardy: howFrontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Cholangiocarcinoma (CHOL) is a tumor with high malignancy and poor prognosis, and its morbidity and mortality have increased significantly in China. The current therapeutic methods have limited efficacy and are easy to be resistant to drugs, and the targeted and immunotherapy still need precise strategy support. FANCB, the core gene of Fanconi anemia (FA) pathway, is involved in DNA damage repair and genome stability maintenance, but its mechanism of action in solid tumors, especially cholangiocarcinoma, has not been clarified. In this study, pan-cancer analysis (TCGA, ICGC, GEO databases) found that FANCB was abnormally high in a variety of cancers and was significantly associated with poor prognosis (such as shortened OS/PFS). Pathway enrichment suggests that it may affect tumor progression by regulating DNA repair, immune response and fibrosis-related pathways. In this study, based on bioinformatics analysis, the pan-cancer map of FANCB and its potential mechanism in cholangiocarcinoma were mapped.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.